A Kaiser Family Foundation poll found that an estimated 1 in 8 US adults has taken a GLP-1 class drug to treat weight loss and obesity-related conditions, with 6% of poll respondents stating they were currently using Eli Lilly and Co.’s obesity drug Zepbound or Novo Nordisk’s Ozempic for diabetes or Wegovy for weight loss. The poll also showed an increased awareness about such treatments, as well as their popularity, despite recent intermittent supply shortages of these drugs.
Full Story: Reuters (5/10)